|
bayesian neural network |
3 |
|
complex human traits |
3 |
|
functional enrichment |
3 |
|
generalized ld score regression |
3 |
|
genome-wide association studies |
3 |
|
gwas summary statistics |
3 |
|
medical image analysis |
3 |
|
partition heritability |
3 |
|
shrinkage priors |
3 |
|
uncertainty estimation |
3 |
|
variational inference |
3 |
|
covid-19 |
2 |
|
drug repurposing |
2 |
|
eqtls |
2 |
|
functional annotation |
2 |
|
genetic association |
2 |
|
network biology |
2 |
|
network pharmacology |
2 |
|
product partition model with covariates (ppmx) |
2 |
|
psychiatric traits |
2 |
|
transcriptome-wide association studies (twas) |
2 |
|
transcriptome-wide association study |
2 |
|
transfer learning |
2 |
|
adolescent |
1 |
|
adult |
1 |
|
aged |
1 |
|
all-cause mortality |
1 |
|
asthma |
1 |
|
attention deficit hyperactivity disorder |
1 |
|
breast tumor |
1 |
|
cause-specific mortality |
1 |
|
dirichlet-laplace |
1 |
|
dose finding |
1 |
|
drug combination |
1 |
|
drug-related side effects and adverse reactions |
1 |
|
female |
1 |
|
genetic risk stratification |
1 |
|
global-local shrinkage prior |
1 |
|
hyperparameter tuning |
1 |
|
lifestyle modification |
1 |
|
maximum tolerated dose |
1 |
|
mrna vaccines |
1 |
|
myocarditis |
1 |
|
non-parametric method |
1 |
|
paracetamol |
1 |
|
passive surveillance system |
1 |
|
phase i trial design |
1 |
|
polygenic risk scores |
1 |
|
posterior consistency |
1 |
|
posterior credible region |
1 |
|
self-controlled case series study |
1 |
|
variable selection |
1 |
